| Schedule of segment information |
| Schedule of segment information | |
| | | |
| | | |
| | |
| | |
Three Months Ended June 30, 2025 | |
| | |
Biotechnology
Segment | | |
Technology
Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | 200,681 | | |
$ | 200,681 | |
| Cost of goods sold | |
| – | | |
| 45,157 | | |
| 45,157 | |
| Total operating expenses | |
| 4,413,385 | | |
| 263,353 | | |
| 4,676,738 | |
| Net loss from operations | |
$ | (4,413,385 | ) | |
$ | (107,829 | ) | |
$ | (4,521,214 | ) |
| | |
Three Months Ended
June 30, 2024 | |
| | |
Biotechnology Segment | | |
Technology Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | – | | |
$ | – | |
| Cost of goods sold | |
| – | | |
| – | | |
| – | |
| Total operating expenses | |
| 2,828,102 | | |
| – | | |
| 2,828,102 | |
| Net loss from operations | |
$ | (2,828,102 | ) | |
$ | – | | |
$ | (2,828,102 | ) |
| | |
| | | |
| | | |
| | |
| | |
Six Months Ended June 30, 2025 | |
| | |
Biotechnology
Segment | | |
Technology
Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | 263,555 | | |
$ | 263,555 | |
| Cost of goods sold | |
| – | | |
| 90,313 | | |
| 90,313 | |
| Total operating expenses | |
| 8,428,087 | | |
| 323,353 | | |
| 8,751,440 | |
| Net loss from operations | |
$ | (8,428,087 | ) | |
$ | (150,111 | ) | |
$ | (8,578,198 | ) |
| | |
Six Months Ended
June 30, 2024 | |
| | |
Biotechnology Segment | | |
Technology Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | – | | |
$ | – | |
| Cost of goods sold | |
| – | | |
| – | | |
| – | |
| Total operating expenses | |
| 5,750,485 | | |
| – | | |
| 5,750,485 | |
| Net loss from operations | |
$ | (5,750,485 | ) | |
$ | – | | |
$ | (5,750,485 | ) |
|